IL27 and inflammatory bowel disease: Previously, we demonstrated that orally administered interleukin-27 (IL-27), luminally delivered to the gastrointestinal mucosa via a Lactococcus lactis bacterial vector, was an effective treatment to attenuate IBD across several mouse models of the disease, including a T-cell transfer model of enterocolitis, acute and chronic DSS-induced colitis and acute severe TNBS-induced colitis [6,7].